| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/03/2022 | 365.12% | HC Wainwright & Co. | $8.5 → $6 | Maintains | Buy |
| 08/08/2022 | 558.91% | HC Wainwright & Co. | $10 → $8.5 | Maintains | Buy |
| 05/18/2021 | 1217.83% | BTIG | → $17 | Initiates Coverage On | → Buy |
| 09/04/2020 | 752.71% | HC Wainwright & Co. | → $11 | Initiates Coverage On | → Buy |
| 08/28/2020 | 830.23% | Wedbush | → $12 | Initiates Coverage On | → Outperform |
| 09/19/2018 | 1682.95% | Baird | → $23 | Initiates Coverage On | → Outperform |
| 05/14/2018 | 1217.83% | Goldman Sachs | → $17 | Initiates Coverage On | → Neutral |
| 05/14/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 05/14/2018 | 1915.5% | Evercore ISI Group | → $26 | Initiates Coverage On | → Outperform |
Surface Oncology Questions & Answers
The latest price target for Surface Oncology (NASDAQ: SURF) was reported by HC Wainwright & Co. on November 3, 2022. The analyst firm set a price target for $6.00 expecting SURF to rise to within 12 months (a possible 365.12% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Surface Oncology (NASDAQ: SURF) was provided by HC Wainwright & Co., and Surface Oncology maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Surface Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Surface Oncology was filed on November 3, 2022 so you should expect the next rating to be made available sometime around November 3, 2023.
While ratings are subjective and will change, the latest Surface Oncology (SURF) rating was a maintained with a price target of $8.50 to $6.00. The current price Surface Oncology (SURF) is trading at is $1.29, which is out of the analyst's predicted range.